Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center
Endocrine-Related Cancer · 2024
DOI: 10.1530/erc-24-0101 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2024. Verfasst von Tugba Barlas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Gazi University, Faculty of Medicine, Ankara, Turkey. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Themen: Patientensicherheit
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) can trigger immune-related adverse events (irAEs). The appearance pattern of irAEs, who is prone to them, and their mechanisms are still uncertain. In this study, we aimed to monitor patients initiated on ICIs for endocrinological aspects and to investigate the potential predictive markers in the development of endocrine-irAEs. The study prospectively included 43 patients with metastatic disease scheduled for anti-PD-1/L1 therapy. Endocrinological follow-up was conducted at specified intervals as well as in response to any additional reported complaints. Serum concentrations of CXCL10, IL-1beta, and IL-17A were measured prior to ICI and during the endocrine-irAEs. A total of 39.5% of the patients experienced endocrine-irAEs, with a median onset time of 3 months. Among patients, 34.9% developed thyroid-related adverse events, and 4.6% experienced hypophysitis. Thyroid autoantibodies were associated with a higher incidence of thyroid-related irAEs ( P = 0.004). In the irAE group, median pre-ICI CXCL10 and baseline thyroid stimulating hormone (TSH) levels were significantly higher, baseline total testosterone level in men was lower than in the non-irAE group ( P < 0.05), whereas IL-1beta and IL-17A levels did not differ ( P > 0.05). Serum CXCL10, IL-1beta, and IL-17A concentrations did not differ significantly pre-ICI and during adverse events ( P > 0.05). Pre-ICI CXCL10 concentration was correlated positively with anti-TPO levels in patients with at least one thyroid autoantibody positivity ( r = 0.706, P = 0.01) and negatively with baseline total testosterone level of men ( r = 0.509, P = 0.002). Our results suggest that higher pre-ICI serum CXCL10 and TSH levels might have a predictive role in the development of endocrinopathies. Besides, baseline thyroid antibody measurements could be beneficial in predicting thyroid dysfunction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Gazi University, Faculty of Medicine, Ankara, Turkey.
- Department of Medical Oncology, Gazi University, Faculty of Medicine, Ankara, Turkey.
ORCID-Profile: Tugba Barlas
Zitieren
APA
Barlas, T., Sutcuoglu, O., Akdogan, O., Balos Toruner, F., Akturk, M., Ozdemir, N., Yazici, O., & Eroglu Altinova, A. (2024). Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center. Endocrine-Related Cancer. https://doi.org/10.1530/erc-24-0101
Vancouver
Barlas T, Sutcuoglu O, Akdogan O, Balos Toruner F, Akturk M, Ozdemir N, et al. Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center. Endocrine-Related Cancer. 2024. doi:10.1530/erc-24-0101
BibTeX
@article{Barlas2024,
author = {Barlas, Tugba and Sutcuoglu, Osman and Akdogan, Orhun and Balos Toruner, Fusun and Akturk, Mujde and Ozdemir, Nuriye and Yazici, Ozan and Eroglu Altinova, Alev},
title = {Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center},
journal = {Endocrine-Related Cancer},
year = {2024},
doi = {10.1530/erc-24-0101}
}
EUVIMED